Search

Displaying results 2641 - 2650 of 10000 in total
  1. Drug

    Technetium Tc-99m exametazime

    go.drugbank.com/drugs/DB09163
    Approved

    It can also be used for the labelling of leukocytes to localise intra-abdominal infections and inflammatory bowel disease. … Technetium Tc-99m exametazime is a radiopharmaceutical sold under the trade name Ceretec used in the detection of altered regional cerebral perfusion in stroke and other cerebrovascular diseases.

    Categories: Compounds used in a research, industrial, or household setting
  2. Drug

    DG041

    go.drugbank.com/drugs/DB05027
    Experimental

    DG041, an anti-platelet compound, has shown to be a selective and potent antagonist of the EP3 receptor for prostaglandins E2. … It block the formation of blood clots mediated through inflammation in atherosclerotic plaques but without increasing bleeding risk.

  3. Drug

    Clioquinol

    go.drugbank.com/drugs/DB04815
    ApprovedVet approvedWithdrawn

    Clioquinol was withdrawn in 1983 due to neurotoxicity.

    Mixtures: LOCACORTENE VİOFORME 0,2 MG/G+30 MG/G KREM, 15 G, LOCACORTENE VİOFORME 0,2 MG/G+30 MG/G KREM, 30 G
  4. Drug

    Ubrogepant

    go.drugbank.com/drugs/DB15328
    ApprovedInvestigational

    [L10926] It was approved by the FDA on December 23, 2019, and is the first oral calcitonin gene-related peptide (CGRP) receptor antagonist approved for the acute treatment of migraine. … [erenumab], [fremanezumab], [galcanezumab]) have also been approved in recent years.[A189207] Ubrogepant was approved by Health Canada on November 10, 2022.

  5. Drug

    Alcloxa

    go.drugbank.com/drugs/DB11205
    Approved

    Mixtures: Watkins Roll On Deodorant, Medi Peel Herbpirin Salt Toothpas Te
  6. Drug

    Andexanet alfa

    go.drugbank.com/drugs/DB14562
    Approved

    It was developed by Portola Pharmaceuticals and was approved in in May 2018. … It is marketed as Andexxa for intravenous injection or infusion and is indicated for the reversal of anticoagulation in combination with [rivaroxaban] and [apixaban] in cases of life-threatening or uncontrolled

  7. Drug

    Guaiacol

    go.drugbank.com/drugs/DB11359
    Approved

    Guaiacol is also present in wood smoke, as a product of pyrolysis of lignin. Guaiacol has been found in the urine of patients with neuroblastoma and pheochromocytoma. … Guaiacol is an agent thought to have disinfectant properties and used as an expectorant. Guaiacol is a phenolic natural product first isolated from Guaiac resin and the oxidation of lignin.

  8. Drug

    Toremifene

    go.drugbank.com/drugs/DB00539
    ApprovedInvestigational

    [A256928] Toremifene possesses tissue-specific actions: it has estrogenic (agonist) activity on the cardiovascular system and on bone tissue and it has weak estrogenic effects on uterine tissue, however … , it also has antiestrogenic (estrogen-antagonist) activity on breast tissue.

  9. Drug

    SIG-001

    go.drugbank.com/drugs/DB17826
    Investigational

    SIG-001 is a cultured human retinal pigment epithelial cell line (ARPE-19) genetically modified with a non-viral vector to express B domain deleted human factor VIII protein, encapsulated within two-layer

  10. Drug

    Beremagene geperpavec

    go.drugbank.com/drugs/DB17831
    ApprovedInvestigational

    Developed by Krystal Biotech, it was first approved by the FDA on May 19, 2023, for the treatment of wounds associated with dystrophic epidermolysis bullosa (DEB). … [L46916] DEB is caused by mutations in the _COL7A1_ gene that encodes collagen VII (COL7), a major component of the anchoring fibrils for dermal–epidermal cohesion.